Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

NCT04338282 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

DRUG: toripalimab

Sponsor

Beijing Tongren Hospital